Selecting CD Treatment in Special Scenarios
Experts in gastroenterology discuss treatment selection in special situations of CD, such as age, women considering pregnancy, and extra-intestinal manifestations.
Read More
Use of Upadacitinib in Treatment of CD
Remo Panaccione, MD, FRCPC, provides an overview of the newest oral therapy approved for CD, upadacitinib.
Sequence Study of Risankizumab vs Ustekinumab in CD
David Rubin, MD, leads the panel discussion on a head-to-head sequence study of rizankizumab vs ustekinumab in the treatment of CD, as well as approaches to choosing first-line treatment.
Role of IL-12/23 Inhibitors and IL-23 Inhibitors in CD
David Rubin, MD, reviews the use of IL-12 and IL-23 inhibitors in the treatment of CD, highlighting ustekinumab and risankizumab for first-line therapy and beyond.
Anti-TNF and Anti-Integrins for Treatment of CD
Experts in gastroenterology provide an overview of anti-TNF (tumor necrosis factor) and anti-integrin therapies in treatment of CD.
Encouraging Patients for Biologic Use in Early Treatment of CD
Sara Horst, MD, MPH, and Miguel Regueiro, MD, comment on the changing treatment landscape of CD, as well as share approaches to communicate with patients about starting biologic treatment early on in CD.
Engaging Patients to Achieve Treatment Goals in CD
Experts in gastroenterology share approaches to engaging patients in achieving treatment targets beyond symptom control.
Monitoring Treatment Response in Treat-to-Target in CD
Experts continue the discussion on treat-to-target in CD, highlighting monitoring treatment response.
Treat-to-Target in CD
Miguel Regueiro, MD, and David Rubin, MD, review the treat-to-target strategy in relation to CD management, and how treat-to-target moves beyond symptom control.
Starting Biologic Treatment Early in CD
Sara Horst, MD, MPH, comments on early introduction of biologics in the treatment of CD, highlighting her approach to initiating conversations with patients about advanced therapy.
Moving Beyond Symptom Control in CD
Experts discuss the idea that, while symptoms of Crohn’s disease (CD) contribute to a patient’s quality of life, symptom control alone is not sufficient and the focus should be modifying the disease process.
Factors Guiding Treatment Choice in Crohn’s Disease
Dr Sara Horst leads the discussion on the commonly followed treatment approach in the community for moderate to severe Crohn's Disease (CD) and highlights the factors that should guide treatment choices.
Key Takeaways and Prospective Treatment Advances
David Hudesman, MD, Maia Kayal, MD, Miguel Regueiro, MD, Anita Afzali, MD, and Millie Long summarize their discussion of Inflammatory Bowel Disease (IBD) and discuss prospective advances in treatment options.
Biosimilar Treatment Options for Patients With UC
Experts discuss the recent use of biosimilars like inolimomab as treatment for ulcerative colitis (UC).
Treatment Sequencing for UC
Experts offer clinical advice on therapy sequencing of Janus kinase (JAK) inhibitors for ulcerative colitis (UC) and when surgery may be appropriate.
Utilizing JAK Inhibitors in Patients With UC
Experts discuss how they utilize Janus kinase (JAK) inhibitors for patients with ulcerative colitis (UC).
The Role of Ustekinumab in UC
Millie Long, David Hudesman, MD, Maia Kayal, MD, and Miguel Regueiro, MD, discuss treatment strategies for ulcerative colitis (UC) utilizing ustekinumab.
The Role of Ozanimod in UC
Miguel Regueiro, MD, discusses the role of ozanimod as a treatment option for ulcerative colitis (UC).
Treatment Approaches for Patients With UC
Anita Afzali, MD, discusses treatment approaches to ulcerative colitis (UC) and how they may differ from Crohn’s Disease (CD).
Major Takeaways for Treating CD
Experts summarize their clinical strategies for monitoring and treating patients with Crohn’s Disease (CD).
Optimizing Therapies for CD
Millie Long, Miguel Regueiro, MD, Maia Kayal, MD, Anita Afzali, MD, and David Hudesman, MD, offer clinical strategies for optimizing treatments for Crohn’s Disease (CD) patients.
Second-Line Therapies for CD
Miguel Regueiro, MD, offers his clinical advice on second-line therapies for patients with Crohn’s Disease (CD).
Selecting Treatments in Patients With EIM
Anita Afzali, MD, David Hudesman, MD, and Maia Kayal, MD, discuss how extra intestinal manifestations (EIM) affect therapy strategies for Crohn’s Disease (CD) patients.
Selecting Therapies for CD in Pregnancy
Millie Long discusses treatment considerations for Crohn’s Disease (CD) patients who are planning for pregnancy.
Efficacy and Safety of Ustekinumab for CD
Experts discuss the results of a five-year efficacy and safety trial of ustekinumab for treatment of Crohn’s Disease (CD).
The Role of Vedolizumab and Risankizumab in CD
Anita Afzali, MD, David Hudesman, MD, Millie Long, and Miguel Regueiro, MD, discuss Vedolizumab and Risankizumab as treatments for Crohn’s Disease (CD).
Selecting First-Line Treatments for CD
David Hudesman, MD, Miguel Regueiro, MD, and Maia Kayal, MD, offer first line treatment strategies for patients with Crohn’s Disease (CD).
Managing Care for IBD Patients Not Responding to Treatment
Experts discuss how to care for Inflammatory Bowel Disease (IBD) patients who are not responding to treatment.
Treatment Factors of IBD
Experts discuss treatment options for patients with Inflammatory Bowel Disease (IBD) and clinical factors to consider.
Overview of IBD
David Hudesman, MD, Maia Kayal, MD, Miguel Regueiro, MD, Anita Afzali, MD, and Millie Long discuss the current treatment landscape for Inflammatory Bowel Disease (IBD).